The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies	B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, T-cell leukemia, acute biphenotypic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm	Recruiting	Phase 1 / Phase 2	2026-04-15		NCT04329728

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AVM Biotechnology Inc	2
Medpace, Inc.	17

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
ASCLEPES Research Centers	Weeki Wachee	United States	1
Baptist Clinical Research Institute	Memphis	United States	13
City of Hope	Duarte	United States	238
Gabrail Cancer Center Research,	Canton	United States	1
Innovative Clinical Research Institute	Whittier	United States	1
Los Angeles Cancer Network	Los Angeles	United States	4
Norton Cancer Institute	Louisville	United States	37
Oncology Hematology West P.C. dba Nebraska Cancer Specialists	Omaha	United States	1
UCLA Medical Center of Hematology/Oncology	Los Angeles	United States	1
University of Illinois at Chicago Cancer Center	Chicago	United States	1
University of Texas(UT) Southwestern-Children's Medical Center	Dallas	United States	1